Independent · evidence-based · non-judgmentalDraft · pending medical review
Not yet medically reviewed — information on this site is in preparation and has not been verified by a medical reviewer.
Drug index / Cannabinoid / THC-P
Cannabinoid

THC-P

(6aR,10aR)-3-heptyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol

THC-P (tetrahydrocannabiphorol) is a cannabinoid that binds the CB1 receptor far more strongly than ordinary THC, making it substantially more potent, and is sold in hemp-derived products. Little is known about its safety, and the 2025 federal hemp law effective November 12, 2026 is expected to make most THC-P products federally illegal.

Overview

THC-P (tetrahydrocannabiphorol) is a cannabinoid identified in cannabis in trace amounts; commercial THC-P is generally synthesized. Its notable feature is potency: laboratory work suggests it binds the CB1 cannabinoid receptor many times more strongly than delta-9 THC, so small amounts can produce strong intoxication. It is sold in hemp-derived vapes, edibles, and blends, often alongside other novel cannabinoids.

Source: peer-reviewed literature (NIH/PMC); Congress.gov (CRS)

Chemistry & mechanism of action

THC-P activates the CB1 cannabinoid receptor, the same receptor behind the delta-9 THC high, but its longer molecular side chain lets it bind far more tightly — in vitro studies report affinity many times higher than delta-9 THC. This much stronger receptor binding is thought to explain its high potency and intense effects at small amounts, though human data are very limited.

Source: peer-reviewed literature (NIH/PMC)

Effects

Users report a strong, THC-like high — relaxation, euphoria, altered perception, heavy sedation — that can be considerably more intense than ordinary THC for a given amount, along with the usual dry mouth, red eyes, and impaired coordination. Because potency is high and products are inconsistently dosed, over-intoxication with anxiety, paranoia, and rapid heart rate is easy to reach.

Source: peer-reviewed literature (NIH/PMC)

Risks & harms

THC-P's core risk is its potency combined with how little is known about it. Because it binds CB1 far more strongly than ordinary THC, doses that seem small can produce intense, longer over-intoxication — pronounced anxiety, paranoia, rapid heart rate, disorientation, and in some cases fainting or vomiting — with edibles especially prone to delayed, severe effects. There is almost no human safety research, so long-term and higher-dose risks are essentially unknown, which is itself a hazard. As with other synthesized hemp cannabinoids, products are poorly regulated and frequently mislabeled, may contain manufacturing by-products, residual solvents, or other unlisted cannabinoids, and potency claims are unreliable. Accidental pediatric exposure from candy-like edibles is a serious danger. Keep away from children; if a child ingests a product, or anyone has severe distress, chest pain, fainting, or cannot be roused, call 911, and Poison Control at 1-800-222-1222 can advise. This page has not yet been medically reviewed.

Source: peer-reviewed literature (NIH/PMC); FDA; Congress.gov (CRS)

Images

Visual references coming soon.

If it’s too intense

If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.

  • Get to a calm, safe space with someone you trust who is sober and can stay with you.
  • Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
  • Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
  • Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
  • A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
  • Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.

With cannabis, anxiety or a racing heart usually pass with time. Sit somewhere calm, sip water, and rest — strong edibles in particular can take hours to ease.

Call 911 (or Poison Control, 1-800-222-1222) right away for chest pain, a very high body temperature, a seizure, unconsciousness, or severe confusion. These are medical emergencies, not something to wait out.

Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.

Forensic dossier

Draft · every field is source-cited or marked “Unknown — pending review”

Identity

IUPAC name
(6aR,10aR)-3-heptyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-olPubChem PUG-REST · retrieved 2026-06-18
SMILES
CCCCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)OPubChem PUG-REST · retrieved 2026-06-18
InChIKey
OJTMRZHYTZMJKX-RTBURBONSA-NPubChem PUG-REST · retrieved 2026-06-18
Synonyms / aliases
thcp, 3-Heptyl-delta-1-thc, Tetrahydrocannabiphorol, THCP, Tetrahydrocannabinol-C7PubChem PUG-REST + seed aliases · retrieved 2026-06-18

Composition

Composition
N/A — single compound (see Identity)

Physical / pill characteristics

Dosage form
Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
Route
Unknown — pending review
Shape
Unknown — pending review
Color
Unknown — pending review
Imprint
Unknown — pending review
Score
Unknown — pending review

Scheduling & legal status

US schedule
Unknown — pending review
International
See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA · retrieved 2026-06-18

Effects

Effects
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Risks

Risks
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Interactions

Interactions
Unknown — pending review

Dosage

Pending medical reviewer

Sources

← Back to the drug index